FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Candlesense
FGEN Mergers

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025.

Related Questions

How will the sale affect FibroGen's cash flow and balance sheet? What valuation did AstraZeneca pay for FibroGen China and how does it compare to similar deals? Will the divestiture impact FibroGen's pipeline and future revenue growth?
Find similar articles on Candlesense globenewswire